Literature DB >> 8418612

The US Renal Data System and the Case-Mix Severity Study.

C R Blagg1.   

Abstract

The US Renal Data System (USRDS), established in 1988 to collect and analyze information on end-stage renal disease (ESRD) patients in the United States and their treatment, is briefly described. A number of special studies have been undertaken by the USRDS. One of these is the Case-Mix Study, which reviewed data from an incident sample of 4,911 patients starting dialysis in 1986 and 1987 who were monitored for 1 to 4 years. Analysis included Cox proportional hazard modeling, which allowed quantification of the effect of various comorbid factors on mortality. Relevant findings included a greater mortality in diabetic patients treated by continuous ambulatory peritoneal dialysis (CAPD) compared with those treated by center hemodialysis. With regard to adequacy of dialysis, prescribed dialysis averaged a Kt/V of 1.0, with 53% of patients having a value of 1.0 or less. Where delivered Kt/V could be calculated, the mean of this was 0.72. The prescribed Kt/V in this sample of patients did not predict mortality, but there was a statistically significant inverse correlation of delivered Kt/V with mortality. It would appear a significant number of patients were being underdialyzed in the United States in 1986 and 1987. The means by which to obtain further information from the USRDS is described.

Entities:  

Mesh:

Year:  1993        PMID: 8418612     DOI: 10.1016/s0272-6386(12)80732-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  2 in total

1.  Renal replacement treatment. CAPD has its limitations.

Authors:  J E Tattersall; R N Greenwood; K Earrington
Journal:  BMJ       Date:  1993-08-07

2.  Effect of robotic assistance on the "learning curve" for laparoscopic hand-assisted donor nephrectomy.

Authors:  S Horgan; C Galvani; M V Gorodner; G R Jacobsen; F Moser; A Manzelli; J Oberholzer; M P Fisichella; D Bogetti; G Testa; H N Sankary; E Benedetti
Journal:  Surg Endosc       Date:  2007-02-08       Impact factor: 4.584

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.